-+ 0.00%
-+ 0.00%
-+ 0.00%

Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visit

PUBT·08/04/2026 12:33:47
Listen to the news
Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visit
  • Corbus reached last patient last visit in its Phase 1b CANYON-1 trial of obesity drug CRB-913.
  • Topline results were not presented yet; data are expected in September 2026.
  • Study aims to show whether the once-daily oral therapy can support meaningful weight loss with tolerability suited for longer-term use.
  • Management positioned CRB-913 as a non-incretin alternative for patients who stop GLP-1 treatments due to side effects or limited benefit.
  • Company also highlighted preclinical findings suggesting lower brain exposure versus monlunabant, a potential differentiator for safety positioning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040830PRIMZONEFULLFEED9803192) on August 04, 2026, and is solely responsible for the information contained therein.